Erasca, Inc. (ERAS) analyst actions
Rating and price-target actions on ERAS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ERAS overview →
4 measured ERAS analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Stockholders to Reach Out | Press release | -1.00% | +0.54% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Stockholders to Reach Out | Press release | -0.58% | -2.19% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Shareholders to Reach Out | Press release | -0.62% | -1.67% | |
| Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma | Press release | -0.50% | +2.51% |
Keep exploring
More ERAS: earnings → · SEC filings → · ERAS overview →